Table 2.
Baseline and tumoral characteristics
| Characteristics | B1 | B2 | B3 | B4 | P value1 |
| Age (yr) | 62 | 61 | 60 | 60 | 0.77 |
| Gender (male,%) | 66 | 73 | 76 | 50 | 0.48 |
| Caucasians (%) | 95 | 99 | 96 | 100 | 0.28 |
| HCV positive (%) | 81 | 77 | 76 | 100 | 0.79 |
| Alcohol (%) | 33 | 33 | 34 | 0 | 1.00 |
| PS (0) (%) | 100 | 95 | 95 | 50 | 0.27 |
| AST (U/L) | 35 | 36 | 37 | 38 | 0.90 |
| ALT (U/L) | 64 | 67 | 69 | 70 | 0.80 |
| GGT (U/L) | 133 | 136 | 144 | 155 | 0.79 |
| Platelets (× 1000/UL) | 110 | 110 | 105 | 90 | 0.35 |
| PT (%) | 73 | 73 | 77 | 79 | 0.72 |
| Albumin (U/L) | 3.5 | 3.4 | 3.3 | 3.3 | 0.28 |
| BT (mg/dL) | 1.2 | 1.3 | 1.3 | 1.4 | 0.22 |
| Creatinine | 0.93 | 0.94 | 0.95 | 0.97 | 0.73 |
| No. of TAE session | 1.7 | 1.9 | 1.9 | 1.9 | 0.20 |
1
P value analysis excluded B4 subgroup (only 2 patients). HCV: Hepatitis C virus; PS: Performance status; AST: Aspartate transaminase; ALT: Alanine transaminase; GGT: Gamma-glutamyl transferase; PT: Prothrombine time; BT: Total bilirubin; TAE: Transarterial embolization.